Cifurtilimab  (Synonyms: SEA-CD40)

Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities^[1][2].

CD40^[1]

Cifurtilimab has enhanced FcγRIIIa binding (~10x greater than parent IgG1 antibody) that drives increased effector function, resulting in more potent immune stimulatory activity than antibodies with muted or selective FcγR binding^[1].
Cifurtilimab exposure results in a distinct signature of responses including activation of APCs, CD8+ and CD4+ T cells and NK cells, and targeted depletion of CD40+ B cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In preclinical mouse models, Cifurtilimab combined with chemotherapeutic agents to drive robust anti-tumor activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1629760-27-5

Liquid

Colorless to light yellow

[Cifurtilimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Neff-LaFord H, et al. SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors. Cancer Research, 2020, 80(16_Supplement): 5535-5535.

  [2]. Zeng W, et al. 438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models. 2020.